Dynavax Technologies Corporation (0IDA.L)
USD 12.91
(-0.26%)
USD 12.91
(-0.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 182.11 Million USD | -60.45% |
| 2022 | 460.53 Million USD | 73.22% |
| 2021 | 265.87 Million USD | 714.53% |
| 2020 | 32.64 Million USD | 106.2% |
| 2019 | 15.83 Million USD | 216.41% |
| 2018 | -13.59 Million USD | -1468.4% |
| 2017 | -867 Thousand USD | -107.85% |
| 2016 | 11.04 Million USD | 172.67% |
| 2015 | 4.05 Million USD | -63.29% |
| 2014 | 11.03 Million USD | -1.95% |
| 2013 | 11.25 Million USD | 15.82% |
| 2012 | 9.71 Million USD | -54.43% |
| 2011 | 21.31 Million USD | -7.21% |
| 2010 | 22.97 Million USD | -41.61% |
| 2009 | 39.33 Million USD | 8.93% |
| 2008 | 36.11 Million USD | 175.91% |
| 2007 | 13.08 Million USD | 215.47% |
| 2006 | 4.14 Million USD | -71.69% |
| 2005 | 14.65 Million USD | -1.06% |
| 2004 | 14.81 Million USD | 1693.22% |
| 2003 | 826 Thousand USD | -42.12% |
| 2002 | 1.42 Million USD | -39.51% |
| 2001 | 2.35 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 61.81 Million USD | 55.21% |
| 2024 Q1 | 39.82 Million USD | -15.1% |
| 2023 Q4 | 46.9 Million USD | -16.66% |
| 2023 Q3 | 56.28 Million USD | 20.49% |
| 2023 Q2 | 46.71 Million USD | 45.01% |
| 2023 Q1 | 32.21 Million USD | -69.9% |
| 2023 FY | 182.11 Million USD | -60.45% |
| 2022 FY | 460.53 Million USD | 73.22% |
| 2022 Q4 | 107 Million USD | 0.57% |
| 2022 Q1 | 74.03 Million USD | -38.85% |
| 2022 Q2 | 173.09 Million USD | 133.82% |
| 2022 Q3 | 106.4 Million USD | -38.53% |
| 2021 Q4 | 121.05 Million USD | 151.26% |
| 2021 Q1 | 58.71 Million USD | 278.97% |
| 2021 Q2 | 37.92 Million USD | -35.41% |
| 2021 Q3 | 48.18 Million USD | 27.05% |
| 2021 FY | 265.87 Million USD | 714.53% |
| 2020 Q4 | 15.49 Million USD | 65.11% |
| 2020 FY | 32.64 Million USD | 106.2% |
| 2020 Q3 | 9.38 Million USD | 525.95% |
| 2020 Q1 | 6.26 Million USD | 7.31% |
| 2020 Q2 | 1.49 Million USD | -76.08% |
| 2019 Q2 | 3.86 Million USD | 127.24% |
| 2019 FY | 15.83 Million USD | 216.41% |
| 2019 Q1 | 1.7 Million USD | 24.18% |
| 2019 Q3 | 4.42 Million USD | 14.6% |
| 2019 Q4 | 5.84 Million USD | 31.92% |
| 2018 Q3 | -6.28 Million USD | -1.09% |
| 2018 FY | -13.59 Million USD | -1468.4% |
| 2018 Q4 | 1.36 Million USD | 121.77% |
| 2018 Q1 | -2.45 Million USD | -109.46% |
| 2018 Q2 | -6.22 Million USD | -153.19% |
| 2017 Q4 | -1.17 Million USD | -2313.21% |
| 2017 Q2 | 105 Thousand USD | -29.05% |
| 2017 Q3 | 53 Thousand USD | -49.52% |
| 2017 Q1 | 148 Thousand USD | -97.97% |
| 2017 FY | -867 Thousand USD | -107.85% |
| 2016 Q4 | 7.29 Million USD | 4401.23% |
| 2016 Q2 | 2.64 Million USD | 181.0% |
| 2016 Q1 | 942 Thousand USD | 37.52% |
| 2016 FY | 11.04 Million USD | 172.67% |
| 2016 Q3 | 162 Thousand USD | -93.88% |
| 2015 Q4 | 685 Thousand USD | -42.34% |
| 2015 Q3 | 1.18 Million USD | -23.35% |
| 2015 FY | 4.05 Million USD | -63.29% |
| 2015 Q2 | 1.55 Million USD | 147.21% |
| 2015 Q1 | 627 Thousand USD | -72.46% |
| 2014 Q1 | 3.49 Million USD | 22.87% |
| 2014 FY | 11.03 Million USD | -1.95% |
| 2014 Q2 | 3.04 Million USD | -12.86% |
| 2014 Q4 | 2.27 Million USD | 3.08% |
| 2014 Q3 | 2.2 Million USD | -27.53% |
| 2013 Q2 | 3.39 Million USD | 62.69% |
| 2013 Q4 | 2.84 Million USD | -2.73% |
| 2013 FY | 11.25 Million USD | 15.82% |
| 2013 Q3 | 2.92 Million USD | -13.71% |
| 2013 Q1 | 2.08 Million USD | 15.45% |
| 2012 FY | 9.71 Million USD | -54.43% |
| 2012 Q1 | 2.35 Million USD | -78.88% |
| 2012 Q2 | 2.68 Million USD | 14.21% |
| 2012 Q3 | 2.87 Million USD | 7.08% |
| 2012 Q4 | 1.8 Million USD | -37.16% |
| 2011 Q4 | 11.12 Million USD | 847.87% |
| 2011 Q3 | 1.17 Million USD | -83.73% |
| 2011 Q2 | 7.21 Million USD | 381.32% |
| 2011 Q1 | 1.49 Million USD | 90.71% |
| 2011 FY | 21.31 Million USD | -7.21% |
| 2010 Q2 | 1.94 Million USD | -75.97% |
| 2010 FY | 22.97 Million USD | -41.61% |
| 2010 Q4 | 786 Thousand USD | -93.11% |
| 2010 Q3 | 11.4 Million USD | 486.02% |
| 2010 Q1 | 8.09 Million USD | 569.89% |
| 2009 FY | 39.33 Million USD | 8.93% |
| 2009 Q1 | 19.09 Million USD | 74.18% |
| 2009 Q2 | 15.63 Million USD | -18.12% |
| 2009 Q3 | 2.65 Million USD | -83.02% |
| 2009 Q4 | 1.2 Million USD | -54.48% |
| 2008 FY | 36.11 Million USD | 175.91% |
| 2008 Q4 | 10.96 Million USD | 27.32% |
| 2008 Q3 | 8.61 Million USD | -11.52% |
| 2008 Q2 | 9.73 Million USD | 60.37% |
| 2008 Q1 | 6.06 Million USD | -40.93% |
| 2007 Q2 | 1.54 Million USD | -10.68% |
| 2007 Q1 | 1.73 Million USD | -0.4% |
| 2007 Q3 | 763 Thousand USD | -50.71% |
| 2007 Q4 | 10.27 Million USD | 1246.66% |
| 2007 FY | 13.08 Million USD | 215.47% |
| 2006 Q4 | 1.74 Million USD | 29.75% |
| 2006 FY | 4.14 Million USD | -71.69% |
| 2006 Q1 | 288 Thousand USD | -52.0% |
| 2006 Q3 | 1.34 Million USD | 153.5% |
| 2006 Q2 | 529 Thousand USD | 83.68% |
| 2005 Q1 | 12.69 Million USD | 417.23% |
| 2005 FY | 14.65 Million USD | -1.06% |
| 2005 Q4 | 600 Thousand USD | 48.51% |
| 2005 Q3 | 404 Thousand USD | -57.61% |
| 2005 Q2 | 953 Thousand USD | -92.49% |
| 2004 Q4 | 2.45 Million USD | -32.92% |
| 2004 FY | 14.81 Million USD | 1693.22% |
| 2004 Q3 | 3.66 Million USD | -33.36% |
| 2004 Q2 | 5.49 Million USD | 71.36% |
| 2004 Q1 | 3.2 Million USD | 353.32% |
| 2003 FY | 826 Thousand USD | -42.12% |
| 2003 Q4 | 707 Thousand USD | 2973.91% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | 96 Thousand USD | 0.0% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2002 FY | 1.42 Million USD | -39.51% |
| 2001 FY | 2.35 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 282.981% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 65.228% |
| Perrigo Company plc | 1.68 Billion USD | 89.162% |
| Illumina, Inc. | 2.74 Billion USD | 93.363% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 98.804% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 2003.795% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.313% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 96.524% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -1713.553% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 98.389% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 1024.499% |
| Waters Corporation | 1.76 Billion USD | 89.659% |
| Biogen Inc. | 7.3 Billion USD | 97.506% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 501.803% |
| Evolus, Inc. | 140.52 Million USD | -29.597% |
| Adicet Bio, Inc. | -6.09 Million USD | 3086.504% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -1131.019% |
| bluebird bio, Inc. | -4.03 Million USD | 4619.032% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -149.247% |
| FibroGen, Inc. | 128.9 Million USD | -41.281% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 94.744% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 684.314% |
| Homology Medicines, Inc. | -7.22 Million USD | 2619.256% |
| Geron Corporation | -123.5 Million USD | 247.46% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 88.002% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 49.696% |
| Myriad Genetics, Inc. | 476.4 Million USD | 61.772% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 62468.836% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 145.667% |
| Zoetis Inc. | 5.83 Billion USD | 96.878% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -60203.642% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 91.604% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 90.437% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 97.884% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 60204.62% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 76.607% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 58284.345% |
| Verastem, Inc. | -62 Thousand USD | 293837.097% |
| Nektar Therapeutics | 53.47 Million USD | -240.546% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 25.525% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 313.712% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 83.338% |
| OPKO Health, Inc. | 318.12 Million USD | 42.753% |
| Exelixis, Inc. | 1.75 Billion USD | 89.639% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 90.142% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 61.732% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -8121.986% |
| Imunon, Inc. | -720 Thousand USD | 25393.852% |
| Blueprint Medicines Corporation | 236.58 Million USD | 23.022% |
| Insmed Incorporated | 239.63 Million USD | 24.002% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 71.405% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -951.545% |
| TG Therapeutics, Inc. | 219.1 Million USD | 16.883% |
| Incyte Corporation | 3.44 Billion USD | 94.707% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 47.044% |